Nuclease-Mediated Safe Harbor Integration for Antibody Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges in achieving durable and safe transgene expression, with existing delivery methods either being unsafe due to random integration or prone to silencing, and therapeutic antibodies are costly and have limitations in pharmacokinetics and tissue accessibility.
Innovation Solution
The use of nuclease-mediated targeted integration into safe harbor genes like the albumin gene for expressing antibody transgenes, employing zinc finger nucleases, TALENs, or CRISPR/Cas systems to ensure precise insertion and durable expression, allowing for controlled antibody production in secretory tissues such as the liver.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If random integration delivery methods (e.g., integrating lentivirus) are used, then durable expression is achieved, but safety deteriorates due to potential activation of oncogenes
Solution Approach 1:
The patent introduces a specific genomic locus as an intermediary 'safe harbor' site between the random integration process and the final transgene insertion. This predetermined locus serves as a mediator that accepts the transgene without causing the harmful effects of random integration, such as oncogene activation, while still providing stable, durable expression. The locus is specifically chosen to be transcriptionally permissive and genetically stable.
Solution Approach 2:
The patent extracts the transgene from the context of random integration and relocates it to a specifically designed safe harbor locus. By removing the transgene from the random integration process and placing it in a controlled, predetermined genomic location, the harmful effects of random integration are eliminated while preserving the benefits of stable integration and durable expression.
2Object-affected harmful factors
If episomal delivery methods (e.g., AAV, plasmid) are used, then safety is maintained, but expression durability deteriorates due to lack of robust replication
Solution Approach 1:
The patent merges the safety advantages of episomal delivery with the durability advantages of integrated delivery by combining a safe delivery vehicle (such as AAV or plasmid) with a targeted integration mechanism (nuclease-mediated insertion into safe harbor locus). This hybrid approach allows the transgene to be delivered safely via episomal methods and then stably integrated into a predetermined genomic location, achieving both safety and long-term durability.
Solution Approach 2:
The patent performs preliminary delivery of the transgene via safe episomal methods, followed by a subsequent integration step. The transgene is first introduced into the cell using a safe delivery vehicle, and then a nuclease is introduced to mediate its integration into the safe harbor locus. This two-step preliminary action ensures safety during delivery while achieving durability through subsequent integration.
3Productivity
If exogenous promoters are used for transgene expression, then high initial expression levels are achieved, but reliability deteriorates due to eventual silencing
Solution Approach 1:
The patent enables the transgene to utilize the endogenous promoter and regulatory elements of the safe harbor locus for its own expression needs. Instead of relying on external exogenous promoters that are subject to silencing, the transgene 'services itself' by harnessing the inherent transcriptional machinery of the genomic locus where it is inserted. This self-service approach provides stable, long-term expression without the silencing problems associated with exogenous promoters.
Solution Approach 2:
The safe harbor locus is designed to be universally permissive for transgene expression, providing a universal platform that can drive expression of various transgenes without silencing. The locus possesses multiple functional elements including strong endogenous promoters, enhancers, and chromatin accessibility features that work together to provide reliable, long-term expression for diverse transgene applications.
4Duration of action of stationary object
If transgene integration is performed to avoid replication-driven loss, then durability is improved, but manufacturing precision deteriorates due to difficulty in achieving high enough expression levels
Solution Approach 1:
The patent creates a locally optimized genomic environment at the safe harbor locus that is specifically tailored for high-level transgene expression. This locus possesses unique local qualities including strong endogenous promoters, active chromatin structure, and favorable epigenetic features that enhance transcription. By targeting integration to this specific location with these favorable local qualities, the patent achieves both durable expression and high expression levels with precise control.
Solution Approach 2:
The patent replaces the mechanical/random process of integration with a targeted, directed process using nuclease-mediated insertion. Instead of relying on random integration mechanics that produce variable expression levels, the patent uses programmable nucleases (such as CRISPR-Cas9, TALENs, or ZFNs) to precisely insert the transgene at the safe harbor locus. This substitution of mechanics allows for predictable, controllable expression levels while maintaining integration durability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables stable and controlled expression of antibodies in target tissues, enhancing safety and durability while reducing production costs and improving tissue accessibility, effectively treating conditions like cancer, autoimmune diseases, and neurological disorders.
Implementation Method 1
nuclease-mediated targeted integration into safe harbor genes like the albumin gene for expressing antibody transgenes, employing zinc finger nucleases, TALENs, or CRISPR/Cas systems to ensure precise insertion and durable expression
Data Source
AI summary
Nucleases and methods of using these nucleases for expressing an antibody from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.